undamentalytics Newsletter
Sign in

Idexx Laboratories cash flow statement

In fiscal 2025, Idexx Laboratories's operations generated $1.18bn of cash; it spent $125m on capital projects, leaving free cash flow of $1.06bn. It returned $1.22bn through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations1751792182222462362223393734004596487565439079291,1821,419
Depreciation and amortisation504648525559697883838896105112115130145158
Stock-based pay121315161718202024253931385060606065
Capital spending513950587861836574116155107120149134121125115
Free cash flow1241401681651681751392742992843045416363947738081,0571,304
Free cash flow after stock pay1131271531491521571192542752592655105983447137489971,239
Share buybacks83143256132368618402304283369302183747820728371,2171,048

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DXCM vs IDXXBLCO vs IDXXIDXX vs RMD

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Idexx Laboratories's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Idexx Laboratories.